NR1I3 and non-small cell lung carcinoma: Finally, we analyzed the profile of hCAR in two TCGA studies and noted that CAR could be an interesting target for NSCLC patients receiving paclitaxel treatment since hCAR is expressed in tumor samples and has no association with OS.